Clinical Trials
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
ASPIRE: Potentially Slowing Lung Fibrosis in IPF
Researchers are examining whether an investigational medication called buloxibutid can slow down lung scarring and improve breathing for people with idiopathic pulmonary fibrosis (IPF). Volunteers are needed. Learn if you are eligible for the ASPIRE IPF trial
BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
BEACON IPF: Bexotegrast as a Potential Treatment for IPF
As part of the BEACON IPF study, researchers are evaluating a new molecule called bexotegrast, which may provide another effective way to treat IPF symptoms.
Biomarkers & Hypersensitivity Pneumonitis Progression
Are biomarkers in the blood of patients with hypersensitivity pneumonitis (HP) predictive? Researchers understand if biomarkers can help doctors understand how quickly the disease will progress
ILD & Early Rheumatoid Arthritis
Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.
LCI Testing Possible Tool for Identifying ILD Risks in Scleroderma Patients
Lung clearance testing may give researchers a new tool to predict people with scleroderma who are at risk of developing interstitial lung disease. Volunteers are needed for a one-visit clinical trial.
Link Between Rheumatoid Arthritis & Lung Disease
Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
.jpg?lang=en-US&ext=.jpg)
PRA023 for Systemic Sclerosis with Interstitial Lung Disease
Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD).
Predicting ILD from Hypersensitivity Pneumonitis
Anyone with hypersensitivity pneumonitis may qualify for this observational study and help researchers find patterns for predicting ILD.
Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
The MIST Clinical Study for PPF
Progressive Pulmonary Fibrosis (PPF) is a rare lung disease that causes scarring in the lung. Researchers are investigating if an inhaled study treatment can help improve lung function with fewer side effects than current treatments.